HC Wainwright & Co. Maintains Buy on Liquidia, Raises Price Target to $65
HC Wainwright & Co. analyst Andrew S. Fein maintains Liquidia (NASDAQ:LQDA) with a Buy and raises the price target from $58 to $65.
Stocks · News reference
Liquidia shares are trading higher after the company announced a global settlement agreement with United Therapeutics, resolving all pending litigation and ensuring YUTREPIA remains available to PAH patients without disruption.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Nasdaq Dips Over 400 Points; Bank of America Shares Tumble After Q3 Results
US stocks fell Wednesday as Nasdaq dropped 1.54% and Dow 0.35%; Bank of America sank 5% after weak results, while oil rose and inflation topped forecasts.
Wells Fargo Maintains Equal-Weight on Liquidia, Raises Price Target to $33
Wells Fargo analyst Benjamin Burnett maintains Liquidia (NASDAQ:LQDA) with a Equal-Weight and raises the price target from $30 to $33.
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mostly fell, but Bending Spoons surged 40% after Berkshire’s $330M investment. Liquidia and Verastem also posted strong gains.